Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 17/20 | 0.81 |
| ▸ | AKT1 | P31749 | 6/20 | 0.73 |
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.49 |
| ▸ | KDM6B | O15054 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15054925 | 0.93 | RPS6KB1 (0.78) | RPS6KB1AKT1AURKAAURKBKDM6B | |
| SCHEMBL15073443 | 0.90 | RPS6KB1 (1.00) | RPS6KB1AKT1AURKAAURKB | |
| SCHEMBL15054932 | 0.84 | RPS6KB1 (1.00) | RPS6KB1AKT1 | |
| SCHEMBL12120508 | 0.80 | RPS6KB1 (0.81) | RPS6KB1AKT1AURKAAURKBEGLN1 | |
| SCHEMBL15054406 | 0.79 | RPS6KB1 (1.00) | RPS6KB1AKT1AURKAAURKB | |
| SCHEMBL15055215 | 0.79 | RPS6KB1 (1.00) | RPS6KB1AKT1AURKAAURKB | |
| SCHEMBL15055368 | 0.79 | RPS6KB1 (1.00) | RPS6KB1AKT1AURKAAURKB | |
| SCHEMBL15054623 | 0.78 | RPS6KB1 (0.70) | RPS6KB1AKT1AURKAAURKB | |
| SCHEMBL3716881 | 0.78 | MAPT (0.70) | RPS6KB1AKT1PKMKDM6BKDM4C | |
| SCHEMBL15073590 | 0.77 | RPS6KB1 (0.75) | RPS6KB1AKT1AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10080753-B2 | Heterocyclic carboxamides as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2018-09-25 | — | — | US | claimed |
| US-20160339028-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-11-24 | — | — | US | claimed |
| US-10080753-B2 | Heterocyclic carboxamides as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2018-09-25 | — | — | US | disclosed |
| US-20160339028-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
| US-20160339028-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
| US-20160339028-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
| EP-2794571-B1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-11-02 | — | — | EP | disclosed |
| EP-2794571-B1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-11-02 | — | — | EP | disclosed |
| US-20160058763-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-03-03 | — | — | US | disclosed |
| US-20160058763-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-03-03 | — | — | US | disclosed |
| US-20160058763-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-03-03 | — | — | US | disclosed |
| US-9139568-B2 | Heterocyclic carboxamides as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| US-9139568-B2 | Heterocyclic carboxamides as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| US-9139568-B2 | Heterocyclic carboxamides as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| EP-2794571-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | Merck Patent GmbH (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-20140309245-A1 | Novel Heterocyclic Carboxamides as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2014-10-16 | — | — | US | disclosed |
| US-20140309245-A1 | Novel Heterocyclic Carboxamides as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2014-10-16 | — | — | US | disclosed |
| US-20140309245-A1 | Novel Heterocyclic Carboxamides as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2014-10-16 | — | — | US | disclosed |
| WO-2013096194-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096194-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058763-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MAP3K19, MAP3K15, MAP3K12 | RPS6KB1 237/4885AKT1 236/4885AURKA 118/4885 |
| US-20140309245-A1 | Novel Heterocyclic Carboxamides as Modulators of Kinase Activity | MAP3K19, MAP3K15, MAP3K12 | RPS6KB1 210/4885AKT1 214/4885AURKA 158/4885 |
| US-10080753-B2 | Heterocyclic carboxamides as modulators of kinase activity | MAP3K15, MAP3K12, MAP3K11 | RPS6KB1 197/4885AKT1 165/4885AURKA 184/4885 |
| US-20160339028-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MAP3K19, MAP3K15, MAP3K12 | RPS6KB1 210/4885AKT1 214/4885AURKA 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.